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1. INTRODUCTION 
Symmetric methylation of cytosine in CpG dinucleotides is one 
of the widespread modifications in animal genomes. It is, 
generally, associated with “closed” (inactive) chromatin state and, 
therefore, negative regulation of transcription. To date, this 
modification has been found both in invertebrates (Drosophila 
melanogaster) (Hung et al., 1999) and in chordates (from Ciona 
intestinalis to mammals) (Simmen et al., 1999). It is known that 
DNA methylation plays an important role in so-called “epigenetic” 
regulation of gene expression-regulation that is not directly 
dependent on primary structure of DNA, but is maintained by 
many protein or non-protein factors (like histone modification, 
chromosome territory, etc., i.e., “epi”-genomic factors). DNA 
methylation affects gene expression directly or indirectly. Some 
transcriptional factors (i.e., Sp1) can interact only with non-
methylated DNA sequences, whereas methylation of cytosine 
abolishes interaction (Clark et al., 1997). This in turn leads to less 
effective transcription of certain genes. On the other hand, there is 
a different mechanism of action of CpG methylation. So-called 
MBD (methyl-DNA-binding domain) proteins (Hendrich and Bird 
1998) specifically recognize modified sequences and attract large 
multiprotein complexes that can change chromatin conformation 
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from “opened” to “closed”. It is generally accepted that DNA 
methylation is a unidirectional process. If any sequence acquires 
CpG methylation then this modification becomes stable and will 
be inherited after cell division. So, both daughter DNA molecules 
will have same pattern of methylation. However, CpG methylation 
is much more dynamic during early embryonic development. 
Epigenetic regulation of gene expression include embryonic 
development, transcription, chromatin structure, X chromosome 
inactivation, genomic imprinting and chromosome stability. 
Consistent with these important roles, a growing number of 
human diseases have been found to be associated with aberrant 
DNA methylation. 
 
1.1 DNA methylation 
In mammals, the considerable regulatory task of progressive 
gene repression has been aided by the covalent addition of a 
methyl group in position 5 of the cytosine base of CpG 
dinucleotides. Extensive investigation into the activities 
responsible for DNA methylation and their roles in a wide number 
of biological processes reinforces the importance of this extra 
layer of genomic complexity (Robertson and Wolffe, 2000; Li, 
2002). 
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DNA methylation occupies up to 70% of the CpG 
dinucleotides in the genome, and represents one of the major 
epigenetic modifications in mammals (Robertson and Wolffe, 
2000). The organization of the mammalian genome is such that 
there is a high density of CpG in the upstream promoter regions in 
most of the approximately 30,000 genes, as well as within gene 
introns and exons (Bird, 2002). This organizational feature and the 
capacity for DNA methylation in mammals lead to the early 
speculation that gene regulation might be highly sensitive to the 
methylation status of these so-called CpG islands (Holliday and 
Pugh, 1975). However, this proved not to be the case, as these 
potential targets for methylation were found to be unmethylated, at 
least for most genes under normal circumstances (Antequera and 
Bird, 1993; reviewed in Meehan and Stancheva, 2001). Notable 
exceptions to this general rule include imprinted genes and those 
of the inactive X-chromosome. Further genomic characterization 
identified other classes of sequence families with significant levels 
of CpG, leading to alternative proposals for the significance of this 
stable and heritable modification. The mammalian genome 
contains an extremely high burden of sequences that have arisen 
due to integration of retrotransposons. Uncontrolled expression of 
these sequences from their viral promoters would result in 
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transcriptional chaos, were it not for the susceptibility of these 
promoters to be repressed by DNA methylation (Yoder et al., 
1997). This regulatory role for DNA methylation has been 
embodied in the genome defense hypothesis, and remains one of 
the significant functions of DNA methylation (Walsh et al., 1998). 
One of the most comprehensively studied roles of DNA 
methylation is the marking of parental alleles by genomic 
imprinting. Imprinted genes are expressed in a non-Mendelian 
fashion, in which parent-of-origin specifies the active allele (Reik 
and Walter, 2001). These genes are essential for fetal growth and 
development, and have been shown to also influence postnatal 
growth trajectories and diverse biological processes, for example, 
affecting thermogenesis in offspring, maternal care and suckling 
behavior, and adult behavior and cognition (Li et al., 1999; Plagge 
et al., 2004). The marking of the active and inactive alleles is 
achieved though differential DNA methylation in critical regulatory 
regions. These differentially methylated regions (DMRs), are 
essential for expression or repression. It is interesting to note that 
a disproportionately high number of imprinted genes are found to 
be methylated on the maternal allele (Reik and Walter, 2001). 
During development in mammals, there are at least two 
periods of genome-wide DNA methylation reprogramming (Reik 
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and Walter, 2001). The two periods best characterized include a 
time during primordial germ cell differentiation and one during 
preimplantation development. The extent of this reprogramming 
and whether, in fact, it is required for normal development in all 
mammalian species remain unknown (Bestor, 2000). In this 
regard, the details of DNA methylation reprogramming in humans 
are only just beginning to be appreciated. The degree to which 
this important regulatory mechanism operates in early 
development and germ cell differentiation in humans will influence 
our understanding of the potential impact of DNA methylation in 
human health and disease. 
A growing body of evidence indicates that DNA methylation, 
together with chromatin modifications, are competent to specify 
transcriptional states and perhaps more importantly, mutually 
reinforce transcriptionally repressive states (Tamaru and Selker, 
2001; Fuks et al., 2003; Tamaru et al., 2003). 
 
1.2 Enzimatic activities and substrates 
Introduction of the methyl group into the symmetrical 
dinucleotide 5-CpG-3 results in its positioning into the major 
groove of the DNA without interference with the base-pairing of 
nucleotides. Methylation of cytosine residues imposes a greater 
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level of risk to the stability of the genome as deamination of 
methyl-cytosine results in the transition of meC-T, a nucleotide 
base change less easily repaired and recognized than the 
deamination of cytosine to uracil (Hermann et al., 2004). The lack 
of high fidelity repair capacity for the meC-T transition explains the 
observation that CG sites are a major mutational hotspot, 
accounting for up to 30% of point mutations in the germline, and 
are decidedly underrepresented in mammalian genomes (Bird et 
al., 1985). This situation suggests that the maintenance of this 
modification and its functions have been the result of considerable 
evolutionary pressure, and that the continued maintenance of 
cytosine methylation must confer a significant advantage given 
the substantial costs. The complexity of DNA methylation in the 
genome suggests that there must be a number of activities 
responsible for its establishment and maintenance, able to 
operate in both specialized and generalized functions (Chen et al., 
2003). 
 
1.3 DNA Methyltransferases 
DNA methyltransferases (MTases) represent a collection of 
three family groups numbered in order of their discovery (Bestor, 
2000). These enzymes serve the two distinctive processes of 
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DNA methylation, the establishment of DNA methylation state by 
de novo methylation and, there after, the maintenance of those 
states by templating this information to daughter strands arising 
from replication (Lei et al., 1996; Okano et al., 1999). Despite 
some sequence similarities, the divisions of labor amongst this 
group can, in part, be inferred by their functional organization. 
Broadly, their organization can be resolved into two functional 
domains; the N-terminal domain comprising regulatory functions 
and the C-terminal catalytic domain (Fig.1) (Bestor, 2000; 
Robertson, 2002). 
Dnmt1 was the first of the group of MTases identified, and is 
the largest of these activities with an extensive N-terminal 
regulatory domain and a smaller C-terminal domain (Bestor et al., 
1988). This large regulatory domain contains a wide variety of 
functional motifs, including a nuclear localization signal, a 
proliferating cell nuclear antigen (PCNA) (Chuang et al., 1997) 
interacting domain, and a replicating foci targeting region 
(Leonhardt et al., 1992). Dnmt1 does not function in the cell in an 
isolated manner, and is capable of interacting with many proteins 
via the N-terminus. This interaction is likely to be facilitated by the 
polybromo domain (PBHD), a hallmark of protein-protein 
interaction (Bestor and Verdine, 1994). Furthermore, this domain  
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has been implicated in a transport role for Dnmt1 to the replication 
foci (Liu et al., 1998). 
Dnmt1 methylates DNA specifically at CG sites, with a strict 
preference for hemimethylated over unmethylated substrates in 
vitro (Pradhan et al., 1997, 1999). It is this preference for 
hemimethylated substrates that forms the basis for its function as 
a maintenance methylase. In this respect, it is not surprising that 
Dnmt1 expression is tightly coordinated with DNA replication. In 
addition to its function as a MTase, Dnmt1 has been shown to be 
associated with a wide variety of chromatin modifying activities, 
including histone methyltransferases, methyl CpG binding 
proteins, and heterochromatin binding protein HP1 (Hermann et 
al., 2004). Collectively, these associations share in common the 
properties of transcriptional repressors leading to the 
understanding that Dnmt1 and, hence, DNA methylation stably 
reinforces chromatin silencing (Bird, 2002). 
The Dnmt2 gene is the most highly conserved of the MTases 
in eukaryotes, found in both organisms that show methylation and 
those that have no detectable DNA methylation. Although it is 
ubiquitously expressed at low levels in most human and mouse 
tissues as well as mouse embryonic stem cells, mice homozygous 
for a Dnmt2 null mutation are viable, and display normal levels of 
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methylation at endogenous sequences (Okano et al., 1998b). 
Introduction of an inducible transgene containing Dnmt2 indicated 
that a genuine methylase activity could be demonstrated, albeit on 
CpT and CpA targets (Kunert et al., 2003). A weak but 
reproducible in vivo methyltransferase activity was recently 
demonstrated for the recombinant protein in mammalian cell lines 
(Liu et al., 2003). 
Dnmt3 family. The highly related enzymes, Dnmt3a and 
Dnmt3b, are encoded by different genes but share the preference 
for methylation of unmethylated CG dinucleotides. This substrate 
preference identifies them as de novo DNA methylases (Okano et 
al., 1998a). Dnmt3a and Dnmt3b are thought to differ 
mechanistically due to inherent differences in the catalytic 
domains, suggesting that Dnmt3a is distributive while Dnmt3b is 
processive (Gowher and Jeltsch, 2002). These intrinsic 
differences allow for an effective division of labor between these 
related de novo methylases. The processive Dnmt3b is more 
suited to methylation of CG-rich regions of the genome, such as 
the CG-rich pericentromeric repeats (Hermann et al., 2004). The 
distributive nature of Dnmt3a requires that it adds back 
methylation to dinucleotides on a target by target basis, and is 
thus implicated in de novo methylation at single genetic loci (Hata 
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et al., 2002). Dnmt3a is the major form in adult tissues, where it 
colocalizes with heterochromatin. In contrast, the isozyme 
Dnmt3a2 is the major form during embryogenesis, and has been 
shown to localize with euchromatin (Chen et al., 2002). 
The third significant member of the Dnmt3 family of enzymes 
is Dnmt3L. This highly degenerate protein shows clear homology 
to Dnmt3a and Dnmt3b, but despite conserved folding like 
MTases, Dnmt3L lacks any catalytic activity but is expressed 
together with Dnmt3a and 3b during gametogenesis and 
embryogenesis (Bourc'his et al., 2001; Hata et al., 2002). Dnmt3a 
and Dnmt3L are essential for establishment of imprinted regions 
in oocytes (Hata et al., 2002). The exact mechanism of this 
process is not fully worked out, but there is the suggestion that the 
sequence specific function of Dnmt3a may require an activator to 
enforce the accuracy of this targeting. In this regard, Dnmt3L may 
function as an activator protein in the methylation of single copy 
genes. 
 
1.4 The methyl-binding proteins: linking DNA methylation 
and chromatine structure 
A. Bird identified the first methyl-DNA-binding activity called 
MeCP1 (methyl-CpG-binding protein 1) (Meehan et al., 1989). 
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This activity included two complexes (400 and 800 kD) consisting 
of different components. It was shown that MeCP1 plays an 
important role in regulation of expression of reporter genes if 
these genes had methylated promotor regions. Then a protein 
called MeCP2 was identified (Lewis et al., 1992). It had a number 
of biochemical and functional characteristics different from 
MeCP1. For example, its molecular weight was about 70 kD and 
only one symmetrically methylated CpG was sufficient for specific 
interaction of MeCP2 with DNA sequence (MeCP1 needed 12 
symmetrically methylated CpGs). Is was shown that for interaction 
with methylated DNA an 85-amino-acid domain in the N-terminal 
part of protein was responsible. This domain was called MBD 
(methyl-DNA-binding domain). An analogous domain was found 
for MBD1 protein (formerly PCM1). 
In 1998, Hendrich and Bird published a paper about 
identification and characterization of a family of methyl-DNA-
binding proteins (Hendrich and Bird 1998). Three new proteins 
MBD2, MBD3, and MBD4 were described in addition to previously 
characterized MBD1 and MeCP2. Expression of all MBD proteins 
was found in almost all somatic tissues. Moreover, methyl-specific 
interaction with DNA and co-localization with constitutive 
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heterochromatin were shown for MBD1, MBD2, and MBD4 
(Fig.1). 
MeCP2 is a protein with molecular weight ~70 kD. It has two 
functional domains-MBD and TRD (transcription repression 
domain). TRD is necessary for interaction of MeCP2 with the 
mSin3A/HDAC nucleosome remodeling complex and plays crucial 
role in repression of transcription of target genes. MeCP2 can also 
interact with other transcriptional factors and co-repressors (like 
SMRT) (Klose and Bird, 2004). 
MeCP2 is the most intensively studied MBD protein because 
conditional brain-specific deletion of this factor leads to generation 
of symptoms analogous to symptoms of Rett syndrome (Johnston 
et al., 2003). Some of these symptoms are mental retardation, 
heavy breathing, stereotyping, memory dysfunctions, etc. Patients 
suffering from Rett syndrome in most cases have point mutations 
in the MeCP2 gene. It is now known that MeCP2 regulates 
expression of BDNF (brain-developed neurotrophic factors) that is 
important for proper development of the nervous system as well 
as memory formation, etc. 
MBD1 is the largest member of the MBD family. It consists of 
~640 amino acid residues and has molecular weight ~75 kD. 
MBD1 interacts with DNA in a methylation-dependent manner in 
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EMSA experiments. But it can repress either methylated or non-
methylated transitory transfected constructs. Moreover, MBD1, 
unlike MBD2 and MBD4, can co-localize with regions of 
constitutive heterochromatin even in cell with aberrant DNA 
methylation maintenance system (i.e., without DNMT1) (Hendrich 
and Bird 1998). 
In early works, only two functional domains of MBD1 were 
described-MBD and a domain consisting of three CxxC-motifs 
(homologous to motifs found in DNA-methyltransferase DNMT1), 
but another domain was described quite soon. This domain (TRD, 
by analogy to transcriptional repression domain of MeCP2) is 
involved in transcriptional repression of reporter constructs as well 
as one of the CxxC-motifs (Ng et al., 2000). 
It was shown at the same time that MBD1 can utilize different 
functional domains for interaction with different proteins. For 
example, TRD is important for interaction with MCAF (MBD1-
containing chromatin-associated factor) (Fujita et al., 2003a). 
Complexes Suv39h1-HP1alpha (Fujita et al., 2003b) and p150-
CAF-HP1 (Reese et al., 2003) interact with the MBD domain. 
MBD1 can also interact with SETDB1 histone-methyltransferase. 
Protein p150-CAF was characterized as a partner of MBD1 in 
a yeast two-hybrid screen. Complex CAF (chromatin associated 
   
16 
factor) takes part in nucleosome assembly after DNA replication 
and maintenance of active/inactive chromatin state. One of three 
subunits of this complex, p150, interacts with HP1 protein and is 
involved in maintenance of inactive heterochromatin. Moreover, 
p150-CAF can interact with PCNA (proliferating cell nuclear 
antigen) during DNA replication. PCNA, in turn, interacts with 
DNMT1. p150-CAF attracts MBD1-SETDB1 complex that leads to 
methylation of lysine 9 of histone H3 and to formation of inactive 
chromatin. 
MBD2 and MBD3 are related proteins. There is a hypothesis 
that genes coding these factors diverged from a common 
precursor. The genes have common exon-intron structure and 
amino acid sequences of MBD2 and MBD3 are identical by 70% 
(Hendrich et al., 1999a). 
But despite these similarities, MBD2 and MBD3 have 
different functions. MBD3 is a structure subunit of one of the major 
chromatin-remodeling complexes-NuRD (nucleosome remodeling 
and histone deacetylase complex) (Zhang et al., 1999), whereas 
MBD2 is only one of the DNA-binding subunits of MeCP1 (Ng et 
al., 1999). Knockout of MBD3 leads to embryonic lethality in mice 
immediately after implantation of the embryo (Hendrich et al., 
2001). Deletion of MBD2 does not have such serious 
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consequences. Moreover, there are no abnormalities either in 
imprinting/X-inactivation or repression of mobile elements in 
MBD2-/- mice. There is only one phenotypic effect of knockout of 
MBD2-abnormal maternal behavior (Hendrich et al., 2001). 
MBD4 is a protein with molecular weight ~60 kD having two 
functional domains-MBD and a glycosylase domain. MBD4 co-
localizes with regions of constitutive heterochromatin and can bind 
methylated DNA in vitro, but despite other MBD-proteins does not 
participate in regulation of gene expression. 
This protein belongs to the mismatch repair system. 
Methylated cytosines are so-called “hot spot” of mutagenesis they 
can be converted to thymines after spontaneous deamination. 
MBD4 is involved in processes of recognition and correction of 
such mutations (Hendrich et al., 1999b). Deletion of MBD4 leads 
to accumulation of mutations and higher frequency of 
carcinogenesis (Miller et al., 2002). 
Kaiso is a unique methyl-DNA-binding protein. It does not 
have classical methyl-DNA-binding domain and interacts with 
DNA via a zinc finger domain consisting of three zinc fingers of 
C2H2 type. Another functional domain of Kaiso is the N-terminal 
120 amino acid BTB/POZ-domain (Prokhortchouk et al., 2001). 
This domain is usually located in the N-terminal part of BTB-
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proteins and serves for homo- or heterodimerization during 
protein-protein interactions. Most BTB-proteins are transcriptional 
repressors. Kaiso was initially identified by a yeast two-hybrid 
screen as a partner of p120-catenin. p120-catenin is an important 
predominantly cytoplasmic protein interacting with and stabilizing 
E-cadherin (Davis et al., 2003). 
It was also shown that Kaiso is a component of double 
MeCP1 complex. It is a part of a rapidly migrating band called 
Kaiso-generated band (KGB) (Prokhortchouk et al., 2001). The 
molecular weight of KGB is ~700 kD. There is a possibility that 
Kaiso-containing complex serves as an effector in signal-
transduction pathway from cell membrane to nucleus and is 
responsible for repression of target genes in response to 
extracellular signals. 
 
1.5 Different functions of MBD2 protein 
The activity of methyl-binding proteins likely depends on their 
association with different molecular partners. The best example of 
a multiple functions methyl-binding protein is MBD2. MBD2 exerts 
different activities depending on its association with different 
partners. MBD2 can be a component of a large protein complex, 
MeCP1, which represses transcription from densely methylated 
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genes. MeCP1 includes HDAC1, HDAC2, and RbAp46/48 
proteins (Ng and Bird 1999; Ng et al., 1999). By this way, MBD2 
targets deacetylase activity at methylated sites. MBD2 can also 
recruit on methylated DNA a different corepressor complex, Mi-
2/NuRD, through its hetrodimerization with MBD3 (Hendrich et al., 
2001; Bowen et al., 2004). Other authors have identified a protein, 
MIZF, that associates with MBD2 and significantly enhances 
HDAC proteins recruitment and activity (Sekimata et al., 2001). In 
addition, MBD2 form a complex with DNA methyltransferase 1 
(DNMT1) on hemimethylated DNA at replication foci and may help 
to establish or maintain the repressed state of chromatin (Tatemat 
et al., 2000). While the above described functions result in 
transcriptional repression, recently it is emerging that when MBD2 
associates with other partners, it may have opposite effects 
resulting in transcriptional activation of methylated genes. In a 
recent study, it was shown that the viral protein Tax can activate 
transcription from the methylated HTLV-1 long terminal repeat 
(LTR) through the interaction with MBD2 (Ego et al., 2005).  
The transcription factor GATA-3 can displace MBD2 from a 
methylated promoter causing the transcriptional reactivation of 
GATA-3 responsive genes (Hutchins et al., 2002). We have 
recently described a novel MBD2 associating protein, MBDin, 
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showing the unique ability to reactivate MBD2-repressed genes 
still in methylated status (Lembo et al., 2003). In the case of 
MBDin-mediated reactivation, as well as for GATA-3, 
transcriptional reactivation occurs prior to demethylation. 
However, MBDin is recruited by MBD2 on methylated DNA and 
acts by interfering with the ability of MBD2 to associate with the 
repressor complex rather than through displacement of MBD2 
from methyl-CpG sites (Lembo et al., 2003). Recently it has been 
shown that MBD2 interacts with RNA helicase A, a component of 
CREB transcriptional co-activator complex (Fujita et al., 2003). All 
these mechanims lead to activation of methylated genes not 
through a possible active demethylase function of MBD2, but, 
rather, through the association of MBD2 with a variety factors that 
can be recruited on methylated DNA and determine different 
interpretations of DNA methylation signals. 
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2 THE AIM OF THIS STUDY 
At current stage, it seems likely that the activity of methyl-
CpG-binding proteins can depend on their association with 
different molecular partners. 
Despite recent studies mainly propose methyl-CpG-binding 
proteins in the hystone deacethylases-mediated transcriptional 
repression it is also possible their role in alternative mechanisms 
and their involvement in other biological functions. This could be 
particulary true for the methyl-CpG-binding protein MBD2 for 
which both repression ability and demethylation activity have been 
described.  
The aim of this study was to identify, using yeast two-hybrid 
screening, molecular partners of MBD2. Here we describe a novel 
MBD2 interacting protein, TACC3, which is able to modulate the 
MBD2-mediated transcriptional functions. We demonstrate that 
MBD2 and TACC3 may interact both at centrosomes in mitosis 
and in the interphase at nucleus. We show that TACC3/MBD2 
may form a complex with histone acetyltransferases and 
reactivate transcription from methylated genes. Our findings 
provide a possible general mechanism by which methylated 
genes can be reactivated through a switch from a closed to an 
open chromatin configuration. 
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3.  MATERIALS AND METHODS  
3.1 Construction of fusion genes and expression plasmids 
For construction of Gal4Binding-Domain (Gal4BD) and 
Gal4Activation-Domain (Gal4AD) fusion genes, different 
fragments were amplified by PCR with pairs of primers linked to 
restriction sites and cloned in pBridge, pSG424 (Sadovsky et al., 
1995) and pGADGH (Clontech) plasmids: pBridge-MBD2 and 
pGal4-MBD2 were obtained by cloning the entire MBD2b coding 
sequence (786 bp) in the pBridge and pSG424 plasmids 
respectively; pBridge-∆MBD2, pBridge-MUT1, pBridge-MUT3 and 
pBridge-MUT4 are deletion mutants of pBridge-MBD2 and were 
obtained by cloning respectively a 471 bp (amino acids positions 
103 to 260), 177 bp (amino acids 103 to 162), 153 bp (amino 
acids 209 to 260), 180 bp (amino acids 156 to 216) fragment of 
the human MBD2 coding sequence in the pBridge plasmids. Used 
primers containing restriction sites (underlined) were: for pBridge-
MBD2, MBD2-1 (5’-AGTCGAATTCATGGATTGCCCGGCCCTCC 
CC-3’) and MBD2-2 (5’-AGTCGGATCCTTAGGCTTCATCTCCAC 
TGTC-3’); for Gal4-MBD2, MBD2-1 and MBD2-3 (5’-
AGTCGAATTCTTAGGCTTCATCTCCACTGTC-3’); for pBridge-
∆MBD2, MBD2-7 (5’-AGTCGAATTCAAACAACCGGTAACCAAG-
3’) and MBD2-2; for pBridge-MUT1, MBD2-7 and MBD2-9 (5’-
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AGTCGGATCCTTATCCTTGAAGACCTTTGGGTAG-3’); for 
pBridge-MUT3, MBD2-11 (5’-AGTCGAATTCCTCTGCAAAGCTTT 
TATTGTC-3’) and MBD2-2; for pBridge-MUT4, MBD2-12 (5’-
AGTCGAATTCC TACCCAAAGGTCTTCAAGGA-3’) and MBD2-
10 (5’-AGTCGGATCCTTAGAC AATAAAAGCTTTGCAGAG-3’) 
(Lembo et al., 2003). For the expression of red fluorescent protein 
(RFP) fused to, pRFPMBD2: was obtained by cloning the entire 
MBD2b coding sequence (786 bp) in the pDsRedN1 plasmid 
(Clontech). Used primers containing restriction sites (underlined) 
were: for RFPMBD2, MBD2-4 (5’-AGTCGAATTCAGCACAATGG 
ATTGCCCGGCCCTCCCC-3’) and MBD2-14 (5’-AGTCGGATCC 
AAGGCTTCATCTCCACTGTCCAT-3’). To construct pMyc-MBD2 
expression vectors, PCR-generated full-length MBD2 was cloned 
into pcDNA3.1A (Invitrogen) plasmid. Used primers containing 
restriction sites (underlined) were: for pMyc-MBD2, MBD2-4 and 
MBD2-5 (5’-AGTCGGATCCGGCTTCATCTCCACTGTCCAT-3’). 
The plasmid hTACC3-pCR2 Topo cloning (kindly provided by 
T.R.J. Lappin) containing the full length TACC3 coding sequence 
(McKeveney et al., 2001), was partially digested with EcoRI and 
the entire TACC3 cDNA was subcloned into the EcoRI sites of 
pCEFL-HA expression vector (Fedele et al., 2000) to generate 
pHA-TACC3. pHA-∆TACC3 expression vector was generated by 
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cloning a 1290 bp TACC3 fragment (amino acids 409 to 837), into 
pCEFL-HA (EcoRI and XbaI sites). Primers used for amplification, 
containing restriction sites (underlined), were: TACC3-EcoRI/F (5'- 
AGTC GAA TTC ATG GAT GAC CCA AAC TTC ATC-3') and 
TACC3-XbaI/R (5'- AGTC TCT AGA AGG TCA GAT CTT CTC 
CAT CTT G-3'). All PCR-derived products as well as subcloning 
junctions were verified by sequence analysis.  
  
3.2 Yeast two-hybrid assay 
We performed yeast two-hybrid screens by yeast mating 
according to the manufacturer’s instructions (Clontech). In the 
screens we used a human HeLa S3 cell line cDNA library 
pretransformed in the Y187 S. cerevisiae strain cloned 
downstream of the Gal4AD in the pGADGH plasmid (Clontech). 
We cloned ‘bait’ sequences downstream of the Gal4BD in the 
pBridge vector (Clontech) and transformed the PJ692A S. 
cerevisiae strain using the lithium acetate method and then 
treated according to the manufacturer’s instructions. The diploid 
strains were plated on high stringency synthetic medium lacking 
histidine, adenine, tryptophan and leucine. His(+), Ade(+) diploid 
colonies were patched on selective plates and assayed for β-
galactosidase activity using a colony-lift filter assay (Breeden and 
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Nasmyth, 1985). Total DNA was prepared from colonies 
displaying a His(+)/Ade(+)/LacZ(+) phenotype and pGADGH 
library plasmids were then rescued after transformation of a 
HB101 –Leu E. coli strain. The isolated pGADGH library plasmids 
were tested for specificity by cotransformation into PJ692A either 
alone or in combination with the pBridgeMBD2 construct or in 
combination with plasmids containing different unrelated baits 
(syntenin, HMGA1 and galectin-1 cDNAs) fused to sequences 
encoding the Gal4BD. The cDNA inserts from specific clones 
were sequenced using the dideoxy termination method (Sanger et 
al., 1977). For measurement of protein interaction, plasmids were 
cotransformed into a yeast strain Y187 and plated on synthetic 
medium lacking tryptophan and leucine. After four days of growth 
colonies were inoculated in liquid SD –Leu/-Trp for 24 hours and a 
liquid assay for β-galactosidase activity was performed according 
to the manufacturer’s instructions (Clontech). 
 
3.3 Isolation of a human shortest TACC3 cDNA clone 
A bone marrow and a brain cDNA libraries in λgt11 were 
purchased from Clontech. A total of about 3x106 clones were 
screened by an in situ plaque hybridization technique (Sambrook 
et al., 1989). The fragment of pGADGH-TACC3 was labeled by 
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random priming procedure (Feinberg and Vogelstein, 1983) and 
used as a probe. Hybridizations were carried out at 60°C, and 
filters were washed under low-stringency conditions (0.6x SSC, 
0.4%SDS at 40°C). Phage DNA was isolated by small-s cale 
purification procedure (Sambrook et al., 1989). Inserts from 
positive clones were sequenced using the dideoxy termination 
method (Sanger et al., 1977). 
 
3.4 Cell culture and transient transfections 
293T, MCF7 and Cos-7 cells were cultured in DMEM 
supplemented with 10% fetal calf serum (Life Technologies).  
Rat thyroid PC Cl3 cell lines were maintained in Coon’s 
modified F12 medium (EuroClone, Milano, Italy) supplemented 
with 5% newborn calf serum (HyClone, Logan, UT) and six growth 
factors (6H), including TSH (1 mU/ml), and insulin (10 mg/ml) as 
previously described (Ambesi-Impiombato et al., 1980).  
Cells were plated at a density of about 5 x 105 per 100 mm 
Petri dish 24 hours before transfections. DNA transfections were 
carried out by calcium phosphate precipitation using Calphos 
(Clontech) or lipofectAMINETM plus reagents (Invitrogen) 
according to the manufacturer’s instructions. For transcription 
assays, cultures were cotransfected with test plasmids (5 µg) and 
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different amounts of effector plasmids as indicated in the text. The 
β-galactosidase (β-Gal) expression plasmid, pSVβ-Gal (Promega) 
(2µg), was used as an internal control for transfection efficiency.  
 
3.5 Methylation analysis 
50 µg of pGAT1700 plasmid (Salvatore et al., 1995) were treated 
with 50 U of SssI methylase (New England Biolabs) at 37°C in the 
presence of 5 mM adenosylmethionine for 8 h. Complete 
methylation of treated plasmids was confirmed by HpaII restriction 
enzyme digestion (data not shown). After transfections, cells were 
harvested and used for transcription assays. Methylation status of 
pGAT1700 plasmid was determined by bisulfite analysis at 
different times after transfections, as previously described (Lembo 
et al., 2003). 
 
3.6 CAT assays 
Chloramphenicol acetyltransferase (CAT) assays were 
performed with different amounts of extracts to ensure linear 
conversion of the chloramphenicol with each extract and results 
are presented as the means of at least three independent 
transfection experiments. For normalization of transfection 
efficiencies we used a β-Gal expression plasmid was included in 
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the co-transfection. Total protein extracts (5 µg) were assayed for 
β-galactosidase activity as previously described (Majello et al., 
1994). The CAT activity was quantified by counting the amount of 
[14C]chloramphenicol converted to the mono-acetylated form 
using the Molecular Dynamics PhoshorimagerTM system. 
 
3.7 Immunoprecipitation and immunoblotting.  
293T and MCF7 cell extracts were prepared in Nonidet P-40 
lysis buffer (1% NP-40, 50 mM Tris-HCl pH 8.0, 150 mM NaCl) 
with proteinase inhibitors (Roche Molecular Biochemicals). 
Immunoprecipitations were performed as described previously 
(Fedele et al., 2000). The samples were immunoprecipitated with 
mouse monoclonal anti-HA (Roche Molecular Biochemicals), 
mouse anti-myc, rabbit anti-HDAC2, goat anti-TACC3 and mouse 
anti-pCAF antibodies (Santa Cruz), anti-MBD2a antibodies 
(Abcam), and resolved on 12% and 10% SDS-PAGE. 
Immunoprecipitated (IP) proteins were analyzed by 
immunoblotting performed by using goat polyclonal anti-HA, 
mouse anti-myc, goat anti-TACC3, rabbit anti-HDAC2, mouse 
anti-pCAF (Santa Cruz) and rabbit anti-MBD2a (Abcam) 
antibodies. Immunoblots were stained with correspondent 
secondary antibodies (Amersham Biosciences) and revealed with 
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the enhanced chemiluminescence detection system (ECL) 
(Amersham Biosciences). 
 
3.8 Drug Treatments and Quantitative RT-PCR analysis 
PC Cl3 cells were treated with different amounts of 
trichostatin A (50-100 µM) (TSA, Invitrogen) or of 5-aza-2’-
deoxycytidine (10-100 µM) (ICN Biomedical Inc.) for 36 hours. 
Total RNA was isolated with TRIzol Reagent (Invitrogen), as 
described in the RNA isolation protocol. QantiTect Reverse 
Transcription kit (QUIAGEN) was used to generate cDNA. The 
following galectin-1-specific primers were used: Gal-1/Fw (5’-
CTCGGGTGGAGTCTTCTGAC-3’) and Gal-1/Rv (5’-
TCCCCAGGTTTGAGATTCAG-3’). Amplification of rat G6PD 
cDNA was used as the endogenous control using the following 
primers: G6/fw (5’-TCCTCTATGTGGAGAATGAACG-3’) and 
G6/rev (5’-TCATTCAGAGCTTTGCCACA-3). Equal amounts of 
total RNA samples (1 µg) were used for cDNA conversion. After a 
15 min incubation at 50°C, RT was inactivated by he ating at 95°C 
for 3 min. The PCR amplifications were then performed using sybr 
green (Applied Biosystems), in a Chromo4 Real Time 
thermocycler (BIORAD) under the following conditions: 1 cycle, 
1,5 min denaturation at 95°C and then 40 cycle of 1 5 s at 95°C 
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and 1 min at 60°C. Each sample was tested in duplic ate, and 
mean values were calculated. Copy number quantification was 
depending on the number of PCR cycle required for threshold 
detection of the fluorescence signal cycle threshold (Ct values) 
(Aerts et al. 2004). The fold induction Galectin-1 mRNA level was 
calculated using the 2-∆∆Ct method (Livak and Schmittgen, 2001). 
The average Ct was calculated for G6PD and Galectin-1 and ∆Ct 
(Ct G6PD - Ct Gal-1) was determined. The ∆∆Ct was used for relative 
quantification using the expression in PC Cl3 cells as a reference 
control. 
 
3.9 Nonradioactive Histone Acetyltransferase Activity Assay 
293T cells were transfected and nuclear extracts 
immunoprecipitated with mouse monoclonal anti-Myc, and 
subjected to the assay. Nuclear proteins were differentially 
extracted by lysing cells in ice-cold hypotonic buffer (0,2% NP-40, 
10 mM HEPES, pH 7.9, 1 mM EDTA, 60 mM KCl). Nuclei were 
separated through a 60% sucrose cushion and lysed in HB buffer 
(250 mM Tris-HCl, pH 7.8, 60 mM KCl) by freeze-and-thaw 
treatment. Nonradioactive HAT assay was done using a HAT 
assay kit (Upstate Biotechnology, Inc.), according to the 
manufacturer’s protocol. Briefly, each immunoprecipitated fraction 
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of nuclear extract, mixed with 100mM acetyl-CoA and 1X HAT 
assay buffer, was incubated on an enzyme-linked immunosorbent 
assay plate precoated with histones H3 and H4 for 5 or 10 min. 
After several washes with TBS, acetylated histones were detected 
using an antiacetyl-lysine rabbit polyclonal antibodies followed by 
the horseradish peroxidase-based colorimetric assay. A 
recombinant pCAF (25 ng) (Upstate Biotechnology, Inc.) was 
used as a positive control. Data were expressed as OD at 450 
nm. 
 
3.10 Immunocytofluorescence 
Cos-7 and NIH3T3 cells were incubated in 8% Bovine serum 
albumin (BSA) in phosphate-buffered saline (PBS) for 1 hour at 
room temperature (RT). Cells were then incubated with primary 
antibodies: goat polyclonal anti-MBD2 antibodies (1:200), mouse 
monoclonal anti-γ-tubulin (Sigma) (1:2000), rabbit polyclonal anti-
MBD2a (Abcam) antibodies and goat polyclonal anti-TACC3 and 
were diluted in 2% BSA- PBS and incubated 2 h at RT. For double 
immunofluorescent staining, the primary antibodies were 
incubated in unison. After extensive washing with PBS, these 
antibodies were detected by appropriate secondary antibodies as 
follows: Alexa Fluor 488-conjugated goat anti-mouse Ig antibodies 
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(Molecular probes), Alexa Fluor 568-conjugated rabbit anti-goat Ig 
antibodies (Molecular probes), Alexa Fluor 568-conjugated goat 
anti-rabbit Ig antibodies and Alexa (Molecular probes) and Fluor 
488-conjugated rabbit anti-goat Ig antibodies (Molecular probes). 
Secondary antibodies were diluted 1:100 in 2% BSA- PBS and 
incubated for 45 min at RT. Cells were then incubated in 
phosphate buffered saline containing 5 µg/ml of 4’,6-diamidino-2-
phenylindole (DAPI) for 10 min at RT. After incubation, the cells 
were washed in PBS and coverslips were mounted with 4.8% 
Mowiol in 50mM Tris pH 8.5. Images were obtained using a Zeiss 
Axioskop MC 100 fitted with a camera and all the images were 
acquired with a 60x Plan-Neofluar objective. Images were 
subjected to scale adjustment using image software (Photoshop, 
Adobe Systems, Inc., San Diego, CA). 
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4. RESULTS 
4.1 Interaction screening  
To identify news partners of the MBD2 protein, we performed 
interaction screening using the two-hybrid system in yeast 
(Clontech) (Fig.2). We have simultaneously analyzed a bone 
marrow and a brain cDNA libraries. A total of about 3x106 clones 
was tested for each library using the short form of MBD2 cDNA, 
MBD2b, as bait (Lembo et al., 2003). After the specificity of 
interaction was assessed (see Materials and Methods), we have 
identified a total of 92 positive clones (41 and 51 from bone 
marrow and brain, respectively). These clones contained cDNA 
inserts between 512 and 2779 bp, and, after sequencing, we 
could divide them in 11 different groups each containing from 3 to 
12 clones with different insert length but containing the same 
cDNAs. Most groups contained clones derived from the same 
library, possibly reflecting the tissue-specific nature of the cDNAs, 
while some others contained identical cDNAs derived from both 
libraries. Interestingly, most groups contained cDNAs encoding for 
transcriptional repressors or activators. We chose to analyze in 
detail Group F, which included 8 clones, all derived from bone 
marrow library and each containing part of the coding sequence of 
transforming acid coiled-coil protein 3, TACC3  
   
34 
 
   
35 
(DDBJ/EMBL/GenBank accession number AJ243997). TACC3 
was a very interesting candidate MBD2 interactor because of its 
capacity to associate with chromatin remodeling factors 
(Gangisetty et al., 2004). TACC3 is a 100 kDa protein belonging 
to the family of TACC proteins including three human members 
(Still et al 2004; Lappin et al., 2002). TACC3 contains three 
domains (Fig. 3A): a conserved N-terminal region of 108 amino 
acids, encoded by exons 2 and 3 in each vertebrate TACC3 gene, 
an highly variable central region and the conserved TACC domain 
(C-terminal region from amino acids 636 to 837) that share about 
60% identity with the C-terminal region of TACC1 and TACC2 
(Still et al., 2004). All the 8 positive clones of group F contained 
the entire TACC domain. The shortest one (pGAD-F3) contained 
TACC3 sequences encoding a 267 amino acids polypeptide (from 
amino acids 571 to 837) indicating that this region of TACC3 is 
sufficient for the interaction with MBD2 (Fig. 3A).  
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4.2 Interaction of MBD2 deletion mutants with TACC3 in yeast 
To narrow the regions of MBD2 able to interact with TACC3, 
deletion experiments were performed in yeast. As shown in Fig. 
3B, deletion of MBD2 N-terminal 103 amino acids (pBridge-
∆MBD2) did not affect the ability of MBD2 to associate with 
TACC3, demonstrating that the methyl binding domain (MBD) is 
dispensable for the interaction. The further removal of 100 amino 
acids at the C-terminus (pBridge-MUT1) abolished the capacity of 
MBD2 to bind TACC3 showing that the C-terminal region is 
necessary for the interaction. The analysis of pBridge-MUT3 and 
pBridge-MUT4 demonstrated that the MBD2 region from amino 
acids 156 to 216 is sufficient for the interaction with TACC3, while 
the extreme C-terminus (amino acids 216-262) is dispensable. 
 
 
 
 
 
 
 
 
 
   
38 
4.3 Immunoprecipitation experiments 
Coimmunoprecipitation experiments were performed to 
investigate whether MBD2 and TACC3 form a complex in 
mammalian cells (Fig. 4). 293T cells were transfected with 
expression vectors containing the myc-tagged full length MBD2 
cDNA (pMyc-MBD2), together with HA-tagged full length TACC3 
cDNA (pHA-TACC3) or a TACC3 mutant form containing the C-
terminal 429 amino acids (pHA-∆TACC3). Subsequently, cell 
lysates were immunoprecipitated with anti-HA antibodies. The 
immunoprecipitated fractions and whole cell extracts were then 
immunoblotted and hybridized with anti-myc or anti-HA antibodies. 
As shown in Fig. 4, both TACC3 and ∆TACC3 
coimmunoprecipitated with MBD2 (Fig. 4A and 4B respectively). 
Empty vectors were also cotransfected as negative controls. 
These results confirm that in mammalian cells MBD2 and TACC3 
form a complex and that the TACC3 C-terminal region (amino 
acids 409 to 837), containing the TACC domain, is sufficient for 
the interaction.  
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4.4 TACC3 affects the activity of methylated promoters 
To explore whether TACC3 could affect the transcriptional 
repression potential of MBD2, we performed transient transfection 
assays into human 293T cells using a methylated promoter. To 
this aim we have used a CAT reporter plasmid (pGAT1700) 
(Salvatore et al., 1995) containing 1700 bp of the mouse galectin-
1 promoter that can be repressed by in vitro DNA methylation 
(Benvenuto et al., 1996) and, when methylated, is bound by 
MBD2 (Lembo et al., 2003). Transcription assays were performed 
after transfection of MBD2 and TACC3 expression vectors, along 
with either unmethylated or in vitro methylated pGAT1700 
construct in 293T cells. The results (Fig. 5) clearly showed that 
TACC3 was able to reactivate, in a dose dependent manner, the 
methylated promoter (Fig. 5). Interestingly, the reactivation was 
much stronger in the presence of overexpressed MBD2, indicating 
that MBD2 is essential for the recruitment of TACC3 on the 
methylated promoter. In contrast, the activity of unmethylated 
pGAT1700 was not significantly affected by either TACC3 or 
MBD2 exogenous expression (data not shown). To exclude that 
reactivation of the methylated promoter was a consequence of a 
demethylation event, we performed, in parallel with transcriptional 
assays, a sodium bisulfite methylation analysis. 
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Seven CpG sites contained in the -177/+11 region of the 
transfected mouse galectin-1 promoter, whose methylation state 
is critical for transcriptional activity (Lembo et al., 2003; Salvatore 
et al., 1998; Chiariotti et al., 1999), were analyzed using mouse-
specific bisulfite-modified primers. No significant change of 
methylation pattern was observed up to 60h after transfection of 
the reporter gene alone or in combination with TACC3 and/or 
MBD2 (data not shown) indicating that the reactivation observed 
in the transcriptional assays occurred when the promoter was still 
in a fully methylated status.  
Finally, we investigated whether TACC3 was able to reactivate 
endogenous methylated genes. We used a rat thyroid cell line, PC Cl3, 
in which galectin-1 endogenous gene is heavily methylated and barely 
expressed (Benvenuto et al., 1996). Our results showed that 
exogenous expression of TACC3, as well as treatment of cells with the 
deacethylase inhibitor TSA or the demethylating drug azacytidine, 
induced a significant increase of endogenous galectin-1 gene 
expression within 36 hours in a dose dependent manner (Fig. 6). 
Moreover our results showed that TACC3 displays a synergistic effect 
with TSA treatment (Fig. 6). 
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4.5 MBD2/TACC3 complex interact with a nuclear histone 
acetyltransferase (pCAF)  
We next investigated potential mechanisms that could account for 
the observed effects of MBD2/TACC3 complex on the activity of 
methylated promoters. Because TACC3 was recently found in a 
protein complex containing endogenous histone 
acetyltransferases (Gangisetty et al., 2004), we hypothesized that 
TACC3 might favor a switch to an open chromatin configuration 
on MBD2-bound promoters. We therefore investigated the 
possibility that MBD2, through the interaction with TACC3, may 
recruit HATs on methylated promoter. To test this hypothesis, we 
used a breast cancer cell line (MCF7) in which endogenous 
TACC3 forms a complex with pCAF (Gangisetty et al., 2004). In 
this cell line, MBD2a and HDAC2 endogenous proteins were 
expressed at detectable levels, as evidenced by western blot 
analysis (Fig. 7). Immunoprecipitation experiments were 
performed using anti-Myc, anti-MBD2a, anti-pCAF and anti-
HDAC2 antibodies, respectively, and western blots were 
performed using the same antibodies and, in addition, the anti-
TACC3 antibodies (Fig. 76). Results showed that both exogenous 
Myc-tagged MBD2b (Fig. 7A) and endogenous MBD2a (Fig. 7B) 
proteins form a complex with pCAF and TACC3. MBD2 could also  
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bind HDAC2, as extensively reported (Ng and Bird, 1999; Ng et 
al., 1999). However, our experiments show that the complexes 
formed with MBD2 by HDAC2 and by TACC3/pCAF were mutually 
exclusive (Fig. 7B). 
In order to investigate whether the formation of 
MBD2/TACC3/pCAF complex is cell cycle specific, similar 
immunoprecipitation experiments were performed in synchronized 
MCF7 cells. Cells were grown 12 hours in the presence of 0.5% 
serum. Immunoprecipitation experiments were performed at time 
points 0, 1, 3, 6, 12, 18 and 24 hours after 10% serum was 
restored. Results showed that the MBD2/TACC3/pCAF complex 
was present at all time points (data not shown) indicating that the 
formation of the complex is not cell cycle specific. 
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4.6 HAT activity associates with MBD2 
The above experiments indicate that MBD2 and the 
acetyltransferase pCAF may be part of a protein complex. Thus, 
we next analyzed whether HAT enzymatic activity could be 
associated with MBD2 and whether TACC3 may favor such 
association. For this purpose, 293T cells were transfected with 
pMyc-MBD2 alone or in combination with pHA-TACC3 expression 
vector. Then, the HAT enzymatic activity, coprecipitating with 
MBD2, was assayed. The assays were performed both on 
histones H3 and H4. The results, presented in Figure 8, showed 
that HAT activity consistently associated with MBD2 protein even 
in the absence of exogenous TACC3 expression. However, 
TACC3 over-expression significantly enhanced the MBD2-
associated HAT activity, in particular when H4 was used as a 
substrate.  
These data suggest that MBD2 associates with HATs in a 
direct manner or, more likely, through different bridge proteins and 
that TACC3 may actively contribute in providing the MBD2 
complex with HAT activity. 
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4.7 Centrosomal localization of MBD2 
Finally, because TACC3 localizes at centrosomes in mitosis 
(Gergely et al., 2000), we tested the possibility that MBD2 protein 
is recruited at centrosomes as well. Asyncronous Cos-7 cells were 
subjected to immunostaining study using goat anti-MBD2 
antibodies (red) and mouse anti-γ-tubulin antibodies (green) as 
centrosomes indicator. In interphase, MBD2 localizes in the 
nucleus (Fig. 9A-a), as exstensively reported (Hendrich et al., 
1998; Hutchins et al., 2002; Lembo et al., 2003). By contrast, 
during different phases of mitosis, MBD2 mainly localizes at 
centrosomes (Fig. 9A-b and 9A-c).  
In order to establish whether MBD2 and TACC3 co-localize in 
interphase nuclei, we performed an immunofluorescence analysis 
in NIH3T3 mouse cells. Results showed that TACC3 partially 
colocalizes with MBD2 at nucleus (Fig. 9B). However, localization 
of TACC3 was diffuse and not limited to the spots of 
hypermethylated DNA which was seen for MBD2 and in 
concordance with possible multiple functions of TACC3 in 
interphase nuclei.  
These observations indicate that TACC3 and MBD2 
associate both in interphase nucleus and at centrosomes during 
cell division. 
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Interestingly, other components of the NuRD complex, such 
as MBD3 and HDAC1, have been recently localized at mitotic 
centrosomes (Sakai et al., 2002). Our findings further support the 
hypotesis that the NuRD complex play a yet uncharacterized, cell 
cycle controlled, role at the centrosomes and suggest that TACC 
proteins may be involved in this subcellular localization during 
mitosis. 
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5. DISCUSSION 
In the present work we show that TACC3 associates with 
MBD2 and may form a complex with histone acetyltransferases 
switching the MBD2-mediated transcriptional repression to 
activation without involving promoter demethylation. 
Searching for MBD2 partners, we have recently 
demonstrated that MBDin, a novel GTPase protein, is able to 
associate with MBD2 and to reactivate methylated genes without 
altering the methylation pattern of the target genes (Lembo et al., 
2003). However, the mechanisms underlying this phenomenon 
remain poorly understood. In the present study we have 
specifically selected other MBD2 partners that might share with 
MBDin a similar activity. Among several clones positive for MBD2 
interaction in yeast, TACC3 was chosen because of its potential 
ability to associate with histone acetyltransferases, as recently 
reported (Gangisetty et al., 2004). Compatibly with a physilogical 
relevance of their interaction, TACC3 and MBD2 are ubiquitously 
expressed in mammalian tissues, even if the relative proportion 
may vary among different tissues. (Hendrich and Bird, 1998; Still 
et al., 2004). 
TACC3 belongs to a recently identified and evolutionary 
conserved protein family referred as TACC (transforming-acidic 
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coiled-coil containing) family (Still et al., 2004; Lappin et al., 2002). 
Mammalian TACC genes encode highly acidic proteins 
characterized by a conserved and unique 200 amino acids coiled-
coil domain termed the “TACC domain”, but lacking significant 
homology outside of this domain. All the TACC proteins are 
associated with the mitotic centrosome/spindle apparatus 
(Gergely et al., 2000), and localize in the nucleus during 
interphase. In particular, for TACC3, the nucleus represents the 
major interphase subcellular localization. Noticeably, as 
mentioned above, it has been recently demonstrated that TACC2 
and TACC3 proteins may form a complex with different histone 
acetyltransferases, including pCAF. Thus, it has been proposed 
that such a mechanism could account for the observed function of 
TACC3 as a transcriptional coactivator of different nuclear factors 
(Gangisetty et al., 2004; Sadek et al., 2000). 
We show that TACC3, as well as MBDin, has the capacity to 
relief the MBD2-mediated transcriptional repression of methylated 
genes even in the absence of demethylation events. The protein 
structure of TACC3 does not display any evident feature in 
common with MBDin and the interaction with MBD2 occurs 
through different regions of this methyl-binding protein. While 
MBDin interacts with the extreme C-terminal of MBD2 (amino 
   
54 
acids 216 to 262) here we found that the same region is not 
essential for the association with TACC3 which, instead, occurs 
through a more proximal portion of MBD2 (amino acids 156 to 
216). This is compatible with a simultaneous binding of the two 
partners to MBD2 and with eventual synergistic activities. 
Moreover, we show that the C-terminal region of TACC3 (amino 
acids 571 to 837) is sufficient for the interaction with MBD2 both in 
yeast and in mammalian cells. This region include the TACC 
domain, raising the possibility that other members of the TACC 
family might associate with MBD2. Further investigation will be 
necessary to verify the occurrence and the functional role of such 
potential multiple interactions. 
While it is well known that MBD2 is an essential component 
of the chromatin repressor complex such as the MeCP1 complex, 
which includes different histone deacetylases (HDAC1 and 
HDAC2), the possibility that MBD2 could form alternative 
complexes with HATs, natural antagonist of deacetylases, has 
been to date poorly investigated. Because TACC3 associates with 
the histone acetyltransferase pCAF (Gangisetty et al., 2004), we 
have addressed the intriguing possibility that MBD2, as a partner 
of TACC3, could also be part of the same complex. 
Coimmunoprecipitation experiments of both exogenous and 
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endogenous proteins showed that this was the case (Fig. 4 and 
Fig. 7). It has been reported that some transcription factors (YY1 
and Sp1) may interact with both HATs and HDACs, thereby 
acquiring an activator or repressor function depending on the 
promoter context or on the presence of other factors (Cress and 
Seto, 2000). Recently, it has been also demonstrated that HAT 
and HDACs directly interact and immunoprecipitate in the same 
fractions (Yamagoe et al., 2003). Our data indicate that, although 
both TACC3/pCAF and HDAC2 may associate with MBD2 in 
MCF7 cells, they are part of distinct complexes (Fig. 4). In any 
case our findings reinforce the general concept that the actual 
activity of a promoter depends on a dynamic equilibrium of HATs 
and HDACs recruitment (Yamagoe et al., 2003) and extend this 
view to the mechanisms regulating the activity of methylated 
promoter. It is likely that methyl binding proteins play a central role 
in the establishment of such equilibrium on methylated genes. In 
fact, our data show that, in addition to HDAC, also HAT enzymatic 
activity associates with MBD2 in vivo. Interestingly, we observed 
that a large amount of HAT activity associates with MBD2 even in 
the absence of TACC3 indicating that TACC3 may favor such 
association but it is not essential. Although our data show that the 
reactivation of methylated galectin-1 gene occurs in a short time in 
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the absence of demethylation events, we cannot exclude the 
intriguing possibility that the acetylation might trigger promoter 
demethylation in a longer period. In conclusion, our data suggest 
that MBD2 is not just a simple mediator of transcriptional 
repression functioning by recruitment of chromatin repressor 
complexes on densely methylated promoters. We wish to propose 
that methyl binding proteins may mediate both transcriptional 
repression and reactivation of methylated genes depending on the 
dynamic equilibrium of enzymatic activities recruited on 
methylated promoters. Different proteins, including TACC3, might 
favor a prevailing recruitment of HAT activity, therefore leading to 
changes of chromatin configuration sufficient to reactivate 
methylated genes even in the absence of demethylation events. 
According to the current models, two possible mechanisms 
account for the reactivation of previously silent methylated genes: 
i) the promoter can be demethylated after interaction of MBD2 
with MBDin and a co-activator protein complex (Lembo et al., 
2003); ii) the TACC3/pCAF complex, can be to compete with 
repressor complex for the association with MBD2 on methylated 
promoter, it is possible that the acetylation might trigger promoter 
demethylation in a longer period. In Figure 10 we have described 
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a possible model of how TACC3 mediates reactivation of 
methylated promoters. 
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Fig. 10 Possible models for reactivation of silent methylated 
genes. Nucleosomes are shown as green cylinders representing 
the core histone complexes with DNA indicated by the black-line 
wrapped around the cylinders. Blue ovals denote acetylation of 
histones. DNA methylation is indicated by red circles. A) A 
transcriptionally inactive promoter adopt a tightly packed 
chromatin structure by the recruitment of methyl-CpG-binding 
proteins and their associated co-repressors and histone 
deacetylases. B) TACC3/pCAF, activator complex, compete with 
repressor complex for the association with MBD2. Consequently 
the chromatin is acetylated and acquires an open conformation 
and the gene is transcribed although still methylated. As a second 
hypothesis MBD2 can bind a demethylating protein and the 
promoter can be reactivated by a demethylation process mediated 
by MBD2. 
 
   
59 
6. ACKNOWLEDGEMENTS 
I am especially grateful to Prof. Carmelo Bruno Bruni in whose 
laboratory this experimental work was performed.  
A very special thank goes to Prof. Lorenzo Chiariotti, who always 
encouraged me handing on me his enthusiasm for scientific research 
and providing me his support and critical advices. 
I would like also to thank all my colleagues, Dr. Raffaela Pero, Dr. 
Francesca Lembo and Dr. Francesco Natale, who supported me on 
my research projects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
60 
7. REFERENCES  
 
Aerts JL, Gonzales MI and Topalian SL. 2004. Selection of 
appropriate control genes to assess expression of tumor antigens 
using real-time RT-PCR. Biotechniques. 36, 84-91. 
 
Ambesi-Impiombato FS, Parks LA and Coon HG. 1980. Culture of 
hormone-dependent functional epithelial cells from rat thyroids. 
Proc. Natl. Acad. Sci. USA, 77, 3455-3459. 
 
Antequera F and Bird A. 1993. Number of CpG islands and genes in 
human and mouse. Proc Natl Acad Sci U S A. 90, 11995-11999. 
 
Benvenuto G, Carpentieri ML, Salvatore P, Cindolo L, Bruni CB 
and Chiariotti L. 1996. Cell-specific transcriptional regulation and 
reactivation of galectin-1 gene expression are controlled by DNA 
methylation of the promoter region. Mol. Cell. Biol. 16, 2736-2743. 
 
Bestor T, Laudano A, Mattaliano R and Ingram V. 1988. Cloning 
and sequencing of a cDNA encoding DNA methyltransferase of 
mouse cells. The carboxyl-terminal domain of the mammalian 
   
61 
enzymes is related to bacterial restriction methyltransferases. J 
Mol Biol. 203, 971-983. 
 
Bestor TH and Verdine GL. 1994. DNA methyltransferases. Curr 
Opin Cell Biol. 6, 380-389. 
 
Bestor TH. 2000. The DNA methyltransferases of mammals. Hum. 
Mol. Genet. 9, 2395-2402. 
 
Bird A, Taggart M, Frommer M, Miller OJ and Macleod D. 1985. A 
fraction of the mouse genome that is derived from islands of 
nonmethylated, CpG-rich DNA. Cell. 40, 91-99. 
 
Bird A. 2002. DNA methylation patterns and epigenetic memory. 
Genes Dev. 16, 6-21. 
 
Bourc'his D, Xu GL, Lin CS, Bollman B and Bestor TH. 2001. 
Dnmt3L and the establishment of maternal genomic imprints. 
Science. 294, 2536-2539. 
 
   
62 
Bowen NJ, Fujita N, Kajita M and Wade PA. 2004. Mi-2/NuRD: 
multiple complexes for many purposes. Biochim Biophys Acta. 
1677, 52-57. 
 
Breeden L and Nasmyth K. 1985. Regulation of the yeast HO gene. 
Cold Spring Harb. Symp. Quant. Biol. 50, 643-650. 
 
Chen T, Ueda Y, Xie S and Li E. 2002. A novel Dnmt3a isoform produced 
from an alternative promoter localizes to euchromatin and its 
expression correlates with active de novo methylation. J Biol Chem. 
277, 38746-54. 
 
Chen T, Ueda Y, Dodge JE, Wang Z and Li E. 2003. Establishment 
and maintenance of genomic methylation patterns in mouse 
embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol. 23, 
5594-5605. 
 
Chiariotti L, Salvatore P, Benvenuto G and Bruni CB. 1999. Control 
of galectin gene expression. Biochimie. 81, 381-388. 
 
   
63 
Chuang LS, Ian HI, Koh TW, Ng HH, Xu G and Li BF. 1997. Human 
DNA-(cytosine-5) methyltransferase-PCNA complex as a target 
for p21WAF1. Science. 277, 1996-2000. 
 
Clark SJ, Harrison J and Molloy PL. 1997. Sp1 binding is inhibited 
by (m)Cp(m)CpG methylation. Gene. 195, 67-71. 
 
Cress WD and Seto E. 2000. Histone deacetylases, transcriptional 
control, and cancer. J. Cell. Physiol. 184, 1-16. 
 
Davis MA, Ireton RC and Reynolds AB. 2003. A core function for 
p120-catenin in cadherin turnover. J. Cell Biol. 163, 525-534. 
 
Ego T, Tanaka Y and Shimotohno K. 2005. Interaction of HTLV-1 
Tax and methyl-CpG-binding domain 2 positively regulates the 
gene expression from the hypermethylated LTR. Oncogene. 24, 
1914-1923. 
 
Fedele, M, Benvenuto G, Pero R, Majello B, Battista S, Lembo F, 
Vollono E, Day PM, Santoro M, Lania L, Bruni CB, Fusco A 
and Chiariotti L. 2000. A novel member of the BTB/POZ family, 
   
64 
PATZ, associates with the RNF4 RING finger protein and acts as 
a transcriptional repressor. J. Biol. Chem. 275, 7894-7901. 
 
Feinberg AP and Vogelstein B. 1983. A technique for radiolabeling 
DNA restriction endonuclease fragments to high specific activity. 
Anal. Biochem. 132, 6-13.  
 
Fujita H, Fujii R, Aratani S, Amano T, Fukamizu A and Nakajima T. 
2003. Antithetic effects of MBD2a on gene regulation. Mol. Cell. 
Biol. 23, 2645-2657. 
 
Fujita N, Watanabe S, Ichimura T, Ohkuma Y, Chiba T, Saya H, 
and Nakao M. 2003a. MCAF mediates MBD1-dependent 
transcriptional repression. Mol. Cell Biol. 23, 2834-2843. 
 
Fujita, N., Watanabe, S., Ichimura, T., Tsuruzoe, S., Shinkai, Y., 
Tachibana, M., Chiba, T., and Nakao, M. 2003b. Methyl-CpG 
binding domain 1 (MBD1) interacts with the Suv39h1-HP1 
heterochromatic complex for DNA methylation-based 
transcriptional repression. J. Biol. Chem., 278, 24132-24138. 
 
   
65 
Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP and Kouzarides T. 2003. 
The methyl-CpG-binding protein MeCP2 links DNA methylation to 
histone methylation. J Biol Chem. 278, 4035-4040. 
 
Gangisetty O, Lauffart B, Sondarva GV, Chelsea DM and Still IH. 
2004. The transforming acidic coiled coil proteins interact with 
nuclear histone acetyltransferases. Oncogene. 23, 2559-2563. 
 
Gergely F, Karlsson C, Still I, Cowell J, Kilmartin J and Raff JW. 
2000. The TACC domain identifies a family of centrosomal 
proteins that can interact with microtubules. Proc. Natl. Acad. Sci. 
USA. 97, 14352-14357. 
 
Gowher H and Jeltsch A. 2002. Molecular enzymology of the 
catalytic domains of the Dnmt3a and Dnmt3b DNA 
methyltransferases. J Biol Chem. 277, 20409-20414. 
 
Hata K, Okano M, Lei H and Li E. 2002. Dnmt3L cooperates with the 
Dnmt3 family of de novo DNA methyltransferases to establish 
maternal imprints in mice. Development. 129: 1983-1993. 
 
Hendrich B and Bird A. 1998. Identification and characterization of a 
   
66 
family of mammalian methyl-CpG binding proteins. Mol Cell Biol. 
18, 6538-47. 
 
Hendrich B, Abbott C, McQueen H, Chambers D, Cross S and Bird 
A. 1999a. Genomic structure and chromosomal mapping of the 
murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes. Mamm. 
Genome. 10, 906-912. 
 
Hendrich B, Hardeland U, Ng HH, Jiricny J and Bird A. 1999b. 
MBD4 is a novel DNA thymine glycosylase that can bind to the 
product of deamination at methylated CpG. Nature. 401, 301-304. 
 
Hendrich B, Guy J, Ramsahoye B, Wilson VA and Bird A. 2001. 
Closely related proteins MBD2 and MBD3 play distinctive but 
interacting roles in mouse development. Genes Dev. 15, 710-723. 
 
Hermann A, Gowher H and Jeltsch A. 2004. Biochemistry and 
biology of mammalian DNA methyltransferases. Cell Mol Life Sci. 
61, 2571-2587. 
 
Holliday R and Pugh JE. 1975. DNA modification mechanisms and 
gene activity during development. Science. 187, 226-232. 
   
67 
 
Hung MS, Karthikeyan N, Huang B, Koo HC, Kiger J, and Shen CJ. 
1999. Drosophila proteins related to vertebrate DNA (5-cytosine) 
methyltransferases.Proc. Natl. Acad. Sci. USA. 96, 11940-11945. 
 
Hutchins AS, Mullen AC, Lee HW, Sykes KJ, High FA, Hendrich 
BD, Bird AP and Reiner SL. 2002. Gene silencing quantitatively 
controls the function of a developmental trans-activator. Mol Cell. 
10, 81-91. 
 
Johnston MV, Mullaney B and Blue ME. 2003. Neurobiology of Rett 
syndrome. J. Child Neurol. 18, 688-692. 
 
Klose RJ and Bird AP. 2004. MeCP2 behaves as an elongated 
monomer that does not stably associate with the Sin3a chromatin 
remodeling complex. J. Biol. Chem. 279, 46490-46496. 
 
Kunert N, Marhold J, Stanke J, Stach D and Lyko F. 2003. A 
Dnmt2-like protein mediates DNA methylation in Drosophila. 
Development. 130, 5083-5090. 
 
   
68 
Lappin TR, Mullan RN, Stewart JP, Morgan NA, Thompson A and 
Maxwell AP. 2002. AINT/ERIC/TACC: an expanding family of 
proteins with C-terminal coiled coil domains. Leuk Lymphoma. 43, 
1455-1459. 
 
Lei H, Oh SP, Okano M, Juttermann R, Goss KA, Jaenisch R and 
Li E. 1996. De novo DNA cytosine methyltransferase activities in 
mouse embryonic stem cells. Development. 122, 3195-205. 
 
Lembo F, Pero R, Angrisano T, Vitiello C, Iuliano R, Bruni CB and 
Chiariotti L. 2003. MBDin, a novel MBD2-interacting protein, 
relieves MBD2 repression potential and reactivates transcription 
from methylated promoters. Mol. Cell. Biol. 5, 1656-1665. 
 
Leonhardt H, Page AW, Weier HU and Bestor TH. 1992. A targeting 
sequence directs DNA methyltransferase to sites of DNA 
replication in mammalian nuclei. Cell. 71: 865-873. 
 
Lewis D, Meehan R, Henzel J, Maurer-Fogy I, Jeppesen P, Klein F, 
and Bird A. 1992. Purification, sequence, and cellular localization 
of a novel chromosomal protein that binds to methylated DNA. 
Cell. 69, 905-914. 
   
69 
 
Li E. 2002. Chromatin modification and epigenetic reprogramming in 
mammalian development. Nat Rev Genet. 3, 662-673. 
 
Li L, Keverne EB, Aparicio SA, Ishino F, Barton SC and Surani 
MA. 1999. Regulation of maternal behavior and offspring growth 
by paternally expressed Peg3. Science. 284, 330-333. 
 
Liu Y, Oakeley EJ, Sun L and Jost JP. 1998. Multiple domains are 
involved in the targeting of the mouse DNA methyltransferase to 
the DNA replication foci. Nucleic Acids Res. 26, 1038-1045. 
 
Liu K, Wang YF, Cantemir C and Muller MT. 2003. Endogenous 
assays of DNA methyltransferases: Evidence for differential 
activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in 
vivo. Mol Cell Biol. 23, 2709-2719. 
 
Livak KJ and Schmittgen TD. 2001. Analysis of relative gene 
expression data using real-time quantitative PCR and the 2(-Delta 
Delta C(T)) method. Methods. 25, 402-408. 
 
   
70 
Majello B, De Luca P, Hagen G, Suske G and Lania L. 1994. 
Different members of the Sp1 multigene family exert opposite 
transcriptional regulation of the long terminal repeat of HIV-1. 
Nucleic Acids Res. 22, 4914-4921. 
 
McKeveney PJ, Hodges VM, Mullan RN, Maxwell P, Simpson D, 
Thompson A, Winter PC, Lappin TR and Maxwell AP. 2001 
Characterization and localization of expression of an 
erythropoietin-induced gene, ERIC-1/TACC3, identified in 
erythroid precursor cells. Br. J. Haematol., 112, 1016-1024. 
 
Meehan RR, Lewis JD, McKay S, Kleiner EL and Bird AP. 1989 
Identification of a mammalian protein that binds specifically to 
DNA containing methylated CpGs. Cell. 58, 499-507. 
 
Meehan RR and Stancheva I. 2001. DNA methylation and control of gene 
expression in vertebrate development. Essays Biochem. 37, 59-70. 
Review. 
 
Meehan RR, Pennings S and Stancheva I. 2001 Lashings of DNA 
methylation, forkfuls of chromatin remodeling. Genes Dev. 15, 
3231-3236. 
   
71 
 
Miller CB, Guy J, Sansom OJ, Selfridge J, MacDougall E, 
Hendrich B, Keightley PD, Bishop SM, Clarke AR and Bird A. 
2002. Suppressed CpG mutability and enhanced tumorigenesis in 
MBD4-deficient mice. Science. 297, 403-405. 
 
Ng HH and Bird A. 1999. DNA methylation and chromatin 
modification. Curr. Opin. Genet. Dev. 9, 158-163. 
 
Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-
Bromage H, Tempst P, Reinberg D. and Bird A. 1999. MBD2 is 
a transcriptional repressor belonging to the MeCP1 histone 
deacetylase complex. Nat. Genet. 23, 58-61. 
 
Ng HH, Jeppesen P and Bird A. 2000. Functional characterisation of 
the methyl-CpG binding protein MBD1.  Mol. Cell Biol. 20, 1394-
1406. 
 
Okano M, Xie S and Li E. 1998a. Cloning and characterization of a 
family of novel mammalian DNA (cytosine-5) methyltransferases. 
Nat. Genet. 19, 219-220. 
 
   
72 
Okano M, Xie S and Li E. 1998b. Dnmt2 is not required for de novo 
and maintenance methylation of viral DNA in embryonic stem 
cells. Nucleic Acids Res. 26, 2536-2540.  
 
Okano M, Bell DW, Haber DA and Li E. 1999. DNA 
methyltransferases Dnmt3a and Dnmt3b are essential for de novo 
methylation and mammalian development. Cell. 99, 247-257. 
 
Plagge A, Gordon E, Dean W, Boiani R, Cinti S, Peters J and 
Kelsey G. 2004. The imprinted signaling protein XL alpha s is 
required for postnatal adaptation to feeding. Nat Genet. 36, 818-
826. 
 
Pradhan S, Talbot D, Sha M, Benner J, Hornstra L, Li E, Jaenisch 
R and Roberts RJ. 1997. Baculovirus-mediated expression and 
characterization of the full-length murine DNA methyltransferase. 
Nucleic Acids Res. 25, 4666-4673.  
 
Pradhan S, Bacolla A, Wells RD and Roberts RJ. 1999. 
Recombinant human DNA (cytosine-5) methyltransferase. I. 
Expression, purification, and comparison of de novo and 
maintenance methylation. J Biol Chem. 274, 33002-33010. 
   
73 
 
Prokhortchouk A, Hendrich B, Jorgensen H, Ruzov A, Wilm M, 
Georgiev G, Bird A and Prokhortchouk E. 2001. The p120 
catenin partner kaiso is a DNA methylation-dependent repressor. 
Genes Dev. 15, 1613-1618. 
 
Reese BE, Bachman KE, Baylin SB and Rountree MR. 2003. The 
methyl-CpG binding protein MBD1 interacts with the p150 subunit 
of chromatin assembly factor 1. Mol. Cell Biol. 23, 3226-3236.  
 
Reik W and Walter J. 2001. Genomic imprinting: parental influence on 
the genome. Nat Rev Genet. 2, 21-32. 
 
Robertson KD and Wolffe AP. 2000. DNA methylation in health and 
disease. Nat Rev Genet. 1, 11-19. 
 
Robertson KD. 2002. DNA methylation and chromatin - unraveling the 
tangled web. Oncogene. 21, 5361-5379. 
 
Sadek CM, Jalaguier S, Feeney EP, Aitola M, Damdimopoulos AE, 
Pelto-Huikko M and Gustafsson JA. 2000. Isolation and 
characterization of AINT: a novel ARNT interacting protein 
   
74 
expressed during murine embryonic development. Mech. Dev. 97, 
13-26. 
 
Sadovsky Y, Webb P, Lopez G, Baxter JD, Fitzpatrick PM, Gizang-
Ginsberg E, Cavailles V, Parker MG and Kushner PJ. 1995. 
Transcriptional activators differ in their responses to 
overexpression of TATA-box-binding protein. Mol. Cell. Biol. 15, 
1554-1563. 
 
Sakai H, Urano T, Ookata K, Kim MH, Hirai Y, Saito M, Nojima Y 
and Ishikawa F. 2002. MBD3 and HDAC1, two components of 
the NuRD complex, are localized at Aurora-A-positive 
centrosomes in M phase. J. Biol. Chem. 277, 48714-48723. 
 
Salvatore P, Contursi C, Benvenuto G, Bruni CB and Chiariotti L. 
1995. Characterization and functional dissection of the galectin-1 
gene promoter. FEBS Lett. 373, 159-163. 
 
Salvatore P, Benvenuto G, Caporaso M, Bruni CB and Chiariotti L. 
1998. High resolution methylation analysis of the galectin-1 gene 
promoter region in expressing and nonexpressing tissues. FEBS 
Lett. 421, 152-158. 
   
75 
Sambrook J, Fritsch EF and Maniatis T. 1989. Molecular cloning: a 
laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold 
Spring Harbor, N.Y. 
 
Sanger F, Nicklen S and Coulson AR. 1977. DNA sequencing with 
chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74, 5463-
5467. 
 
Sekimata M, Takahashi A, Murakami-Sekimata A and Homma Y. 
2001. Involvement of a novel zinc finger protein, MIZF, in 
transcriptional repression by interacting with a methyl-CpG-
binding protein, MBD2. J. Biol. Chem. 276, 42632-42638. 
 
Simmen MW, Leitgeb S, Charlton J, Jones SJ, Harris BR, Clark VH 
and Bird A. 1999. Nonmethylated transposable elements and 
methylated genes in a chordate genome. Science. 283,1164-7. 
 
Still IH, Vettaikkorumakankauv AK, DiMatteo A and Liang P. 2004. 
Structure-function evolution of the transforming acidic coiled coil 
genes revealed by analysis of phylogenetically diverse organisms. 
BMC Evol Biol. 4, 16. 
 
   
76 
Tamaru H and Selker EU. 2001. A histone H3 methyltransferase 
controls DNA methylation in Neurospora crassa. Nature. 414, 
277-283. 
 
Tamaru H, Zhang X, McMillen D, Singh PB, Nakayama J, Grewal 
SI, Allis CD, Cheng X and Selker EU. 2003. Trimethylated lysine 
9 of histone H3 is a mark for DNA methylation in Neurospora 
crassa. Nat Genet. 34, 75-79. 
 
Tatemat KI, Yamazaki T and Ishikawa F. 2000. MBD2-MBD3 
complex binds to hemi-methylated DNA and forms a complex 
containing DNMT1 at the replication foci in late S phase. Genes 
Cells. 5, 677-688. 
 
Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A and 
Reinberg D. 1999. Analysis of the NuRD subunits reveals a 
histone deacetylase core complex and a connection with DNA 
methylation. Genes Dev. 13, 1924-1935. 
 
Walsh CP, Chaillet JR and Bestor TH. 1998. Transcription of IAP 
endogenous retroviruses is constrained by cytosine methylation. 
Nat Genet. 20, 116-117. 
   
77 
Yamagoe S, Kanno T, Kanno Y, Sasaki S, Siegel RM, Lenardo MJ, 
Humphrey G, Wang Y, Nakatani Y, Howard BH and Ozato K. 
2003. Interaction of histone acetylases and deacetylases in vivo. 
Mol. Cell. Biol. 23, 1025-1033. 
 
Yoder JA, Walsh CP and Bestor TH. 1997. Cytosine methylation and 
the ecology of intragenomic parasites. Trends Genet. 13, 335-
340. 
 
